// App-Quantinova.ai

4649 : ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of prostate and breast cancer

Researchers

Presenter

  • Mari Bjorkman

Principal Investigators

  • Elina Mattila

  • Reetta Riikonen

  • Chandra Sekhar

  • Mahaboobi Jaleel

  • Sivapriya Marappan

  • Tarja Ikonen

  • Daniel Nicorici Nicorici

  • Juha Rantala

  • Susanta Samajdar

  • Murali Ramachandra

  • Pekka Kallio

  • Anu-Maarit Moilanen

Medical Centers

  • Orion Corporation Orion Pharma, Turku and Espoo, Finland

  • Aurigene Discovery Technologies Ltd, Bangalore, India

  • Orion Corporation Orion Pharma, Turku and Espoo, Finland

  • Misvik Biology, Turku, Finland.

Locations

  • Finland

  • India

Companies

  • Orion Corporation

  • Aurigene Discovery T

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • cMYC

Drug/Treatment

  • Enzalutamide

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved